Furthermore, a recent study showed that imatinib-resistant GIST is highly affected by cyclin D1 targeting via proteasome inhibitors, which often leads to cell cycle arrest as well as the expression of p53 and p21 [88]. Here, TP53 is linked to gastrointestinal stromal tumor.